Novartis's Kymriah does not meet primary endpoint in late-st
"With a positive outcome, the consensus for peak sales would probably have gone above $2 billion from currently a little over $1 billion," analyst Laurent Flamme wrote. --------------------------------------------------------------- Just an example of how much in potential sales one of the big Pharmas lose when they don't meet endpoint in one type of cancer. Hopefully our Pela can help them with that. ---------------------------------------------------------------- ZURICH, Aug 24 (Reuters)-NovartisNOVN.Ssaid its KymriahCAR-T therapy did not meet its primary endpoint of event-free survival in a phase III study in patients withaggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment. The safety profile was consistent with the established safety profile of Kymriah and Novartis will complete a full evaluation of the BELINDA study data, the Swiss drugmaker said in a statement on Tuesday. ZKB, which rates the stock overweight, called the news negative in a note to investors. --------------------------------------------------------- Cheers!